4DMedical Secures Major Contract with Intermountain Health for PHA™ Product

The latest announcement is out from 4DMedical Ltd ( (AU:4DX) ).

4DMedical Limited has secured a commercial contract with Intermountain Health, a prominent U.S. health system, for its FDA-cleared Pulmonary Hypertension Analysis (PHA™) product. This contract, facilitated through a strategic partnership with Nuance Communications, marks the first major deployment of the PHA™ algorithm in a large health network, enhancing clinical decision-making and potentially expanding 4DMedical’s market presence. The agreement represents a significant opportunity for revenue growth as it transitions to full commercial terms, with plans to increase usage and expand to other products within the health system.

More about 4DMedical Ltd

4DMedical Limited (ASX:4DX) is a global medical technology company specializing in respiratory care through advanced imaging and AI-powered solutions. Their patented XV Technology® platform quantifies ventilation throughout the lungs, aiding in the precise diagnosis of respiratory diseases. The company’s solutions integrate into existing hospital systems via a SaaS model, transforming routine imaging into diagnostic tools. In December 2023, 4DMedical expanded its capabilities by acquiring Imbio, enhancing its AI-driven platforms for chronic lung and cardiothoracic diseases.

YTD Price Performance: -38.54%

Average Trading Volume: 995,115

Technical Sentiment Signal: Buy

Current Market Cap: A$132.9M

Learn more about 4DX stock on TipRanks’ Stock Analysis page.